Dr. Schacter brings more than 30 years combined oncology experience in clinical research
and the medical field
MORRISVILLE, N.C. (Business Wire) February 26, 2014 – Clinipace Worldwide, a global digital contract research organization (dCRO), today announced the addition of industry veteran, Lee Schacter, PhD, MD, FACP, as Executive Medical Director, working to advance the company’s oncology franchise.
In this role, Dr. Schacter will provide strategic guidance, program design, and medical oversight to clients conducting oncology development programs.
“Coming off a year of significant growth during which we saw our depth and breadth of expertise managing oncology trials remain one of our strongest core competencies, it was critical for us to expand our team of experts in that field,” explained Mark Harvill, COO, Clinipace Worldwide. “Dr. Schacter is a perfect fit as he comes to us as a highly experienced drug development expert, board certified internist, and medical oncologist with extensive experience in development and regulatory strategy.”
Prior to Clinipace, Dr. Schacter was an independent consultant with Phasen Consulting, during which time he served as acting CMO of the Multiple Myeloma Research Foundation, worked with Janssen R&D, and served as medical director for marketed oncology products at AstraZeneca. He also worked as Senior Director, Global Medical Affairs, for Pfizer, Executive Medical Director, Global Head Oncology, with MDS Pharma Services, and various other positions with Yale School of Medicine, Bristol Myers, and other organizations.
Dr. Schacter received his PhD from Brandeis University and his BA from Haverford College. He earned his MD from the University of Miami, spent his internship at Baltimore City Hospitals, was an NIH Post-Doctoral Fellow at Johns Hopkins Cancer Center, and served his residency and fellowship with the Cleveland Clinic. He is a board certified internist, as well as a board certified medical oncologist.
About Clinipace Worldwide
As a global full-service digital contract research organization (dCRO), we have pioneered an innovative technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms. Powered by TEMPO™, our proprietary eClinical platform, our team of experts brings extensive therapeutic knowledge and insight into assisting life science firms in developing and executing regulatory strategies, clinical development, and post-approval research to ensure a successful drug and medical device development program. We have managed over 1,200 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects in therapeutic areas such as cardiovascular & metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies). Clinipace Worldwide is headquartered in Research Triangle Park, North Carolina with offices in Irvine (CA), Boulder (CO), Overland Park (KS), Zurich (CH), Munich (DE), London (UK), Tel-Aviv (IL), Sao Paulo (BR), Buenos Aires (AR), Trivandrum Kerala (IN) and New Delhi (IN). For more information, visit our website at www.clinipace.com.